REGISTERED NUMBER: |
UNAUDITED FINANCIAL STATEMENTS |
FOR THE YEAR ENDED 30 SEPTEMBER 2023 |
FOR |
SANDEXIS MEDICINAL CHEMISTRY LTD |
REGISTERED NUMBER: |
UNAUDITED FINANCIAL STATEMENTS |
FOR THE YEAR ENDED 30 SEPTEMBER 2023 |
FOR |
SANDEXIS MEDICINAL CHEMISTRY LTD |
SANDEXIS MEDICINAL CHEMISTRY LTD (REGISTERED NUMBER: 07767700) |
CONTENTS OF THE FINANCIAL STATEMENTS |
FOR THE YEAR ENDED 30 SEPTEMBER 2023 |
Page |
Company Information | 1 |
Balance Sheet | 2 |
Notes to the Financial Statements | 4 |
Report of the Accountants | 8 |
SANDEXIS MEDICINAL CHEMISTRY LTD |
COMPANY INFORMATION |
FOR THE YEAR ENDED 30 SEPTEMBER 2023 |
DIRECTORS: |
REGISTERED OFFICE: |
REGISTERED NUMBER: |
ACCOUNTANTS: |
45 Queen Street |
Deal |
Kent |
CT14 6EY |
SANDEXIS MEDICINAL CHEMISTRY LTD (REGISTERED NUMBER: 07767700) |
BALANCE SHEET |
30 SEPTEMBER 2023 |
2023 | 2022 |
Notes | £ | £ | £ | £ |
FIXED ASSETS |
Tangible assets | 4 |
CURRENT ASSETS |
Debtors | 5 |
Investments | 6 |
Cash at bank |
CREDITORS |
Amounts falling due within one year | 7 |
NET CURRENT ASSETS |
TOTAL ASSETS LESS CURRENT LIABILITIES |
PROVISIONS FOR LIABILITIES | 8 |
NET ASSETS |
CAPITAL AND RESERVES |
Called up share capital | 9 |
Fair value reserve | 10 | ( |
) | ( |
) |
Retained earnings | 979,628 | 786,570 |
SHAREHOLDERS' FUNDS |
The directors acknowledge their responsibilities for: |
(a) | ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and |
(b) | preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company. |
SANDEXIS MEDICINAL CHEMISTRY LTD (REGISTERED NUMBER: 07767700) |
BALANCE SHEET - continued |
30 SEPTEMBER 2023 |
In accordance with Section 444 of the Companies Act 2006, the Statement of Income and Retained Earnings has not been delivered. |
The financial statements were approved by the Board of Directors and authorised for issue on |
SANDEXIS MEDICINAL CHEMISTRY LTD (REGISTERED NUMBER: 07767700) |
NOTES TO THE FINANCIAL STATEMENTS |
FOR THE YEAR ENDED 30 SEPTEMBER 2023 |
1. | STATUTORY INFORMATION |
Sandexis Medicinal Chemistry Ltd is a |
The Financial Statements are presented in round pounds sterling £. |
2. | ACCOUNTING POLICIES |
Basis of preparing the financial statements |
Turnover |
Turnover represents net invoiced sales of services, excluding value added tax. |
Revenue is recognised when the service is 100% complete. |
Tangible fixed assets |
Fixtures and fittings | - |
Computer equipment | - |
Tangible fixed assets are tested for impairment annually. |
It is the Company's policy to capitalise items with an estimated useful life in excess of two years, and for |
amounts in excess of £250. |
Taxation |
Taxation for the year comprises current and deferred tax. Tax is recognised in the Statement of Income and Retained Earnings, except to the extent that it relates to items recognised in other comprehensive income or directly in equity. |
Current or deferred taxation assets and liabilities are not discounted. |
Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date. |
Deferred tax |
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date. |
Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference. |
Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. |
Hire purchase and leasing commitments |
Rentals paid under operating leases are charged to profit or loss on a straight line basis over the period of the lease. |
Pension costs and other post-retirement benefits |
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate. |
SANDEXIS MEDICINAL CHEMISTRY LTD (REGISTERED NUMBER: 07767700) |
NOTES TO THE FINANCIAL STATEMENTS - continued |
FOR THE YEAR ENDED 30 SEPTEMBER 2023 |
3. | EMPLOYEES AND DIRECTORS |
The average number of employees during the year was |
4. | TANGIBLE FIXED ASSETS |
Fixtures |
and | Computer |
fittings | equipment | Totals |
£ | £ | £ |
COST |
At 1 October 2022 |
Additions |
At 30 September 2023 |
DEPRECIATION |
At 1 October 2022 |
Charge for year |
At 30 September 2023 |
NET BOOK VALUE |
At 30 September 2023 |
At 30 September 2022 |
5. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
2023 | 2022 |
£ | £ |
Trade debtors |
Other debtors |
Directors' current accounts | 116,482 | 54,144 |
Deferred tax asset |
Prepayments |
6. | CURRENT ASSET INVESTMENTS |
2023 | 2022 |
£ | £ |
Unlisted investments | 590,771 | 355,018 |
7. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |
2023 | 2022 |
£ | £ |
Trade creditors |
Tax |
Social security and other taxes |
VAT | 32,765 | 18,598 |
Other creditors |
Accrued expenses |
SANDEXIS MEDICINAL CHEMISTRY LTD (REGISTERED NUMBER: 07767700) |
NOTES TO THE FINANCIAL STATEMENTS - continued |
FOR THE YEAR ENDED 30 SEPTEMBER 2023 |
8. | PROVISIONS FOR LIABILITIES |
2023 |
£ |
Deferred tax |
Accelerated capital allowances |
Other timing differences | 2,438 |
2,612 |
Deferred |
tax |
£ |
Balance at 1 October 2022 | ( |
) |
Provided during year |
Balance at 30 September 2023 |
9. | CALLED UP SHARE CAPITAL |
Allotted, issued and fully paid: |
Number: | Class: | Nominal | 2023 | 2022 |
value: | £ | £ |
Ordinary | £1 | 9,999 | 9,999 |
10. | RESERVES |
Fair |
value |
reserve |
£ |
At 1 October 2022 | ( |
) |
Reserves transfer | 7,900 |
At 30 September 2023 | ( |
) |
SANDEXIS MEDICINAL CHEMISTRY LTD (REGISTERED NUMBER: 07767700) |
NOTES TO THE FINANCIAL STATEMENTS - continued |
FOR THE YEAR ENDED 30 SEPTEMBER 2023 |
11. | DIRECTORS' ADVANCES, CREDITS AND GUARANTEES |
During the year the following Directors Current Accounts subsisted; |
1- a member of key management personnel |
During the year the Director repaid the Company £333 - (2022 - £373) |
During the year the Company advanced the Director £65,000 - (2022 - £352) |
As at the year end the Director owed the Company £84,562 - (2022: £19,895) |
The loan is at a market rate of interest and repayable upon demand. |
2- a member of key management personnel |
During the year the Director repaid the Company £1,066 - (2022 - £1,473) |
During the year the Company advanced the Director £NIL - (2022 - £NIL) |
As at the year end the Director owed the Company £15,301 - (2022 - £16,368) |
The loan is at a market rate of interest and repayable upon demand. |
3- a member of key management personnel |
During the year the Director repaid the Company £1,263 - (2022 - £1,448) |
During the year the Company advanced the Director £NIL - (2022 - £NIL) |
As at the year end the Director owed the Company £16,619 - (2022: £17,882) |
The loan is at a market rate of interest and repayable upon demand. |
SANDEXIS MEDICINAL CHEMISTRY LTD |
REPORT OF THE ACCOUNTANTS TO THE DIRECTORS OF |
SANDEXIS MEDICINAL CHEMISTRY LTD |
The following reproduces the text of the report prepared for the directors in respect of the company's annual unaudited financial statements. In accordance with the Companies Act 2006, the company is only required to file a Balance Sheet. Readers are cautioned that the Income Statement and certain other primary statements and the Report of the Directors are not required to be filed with the Registrar of Companies. |
As described on the Balance Sheet you are responsible for the preparation of the financial statements for the year ended 30 September 2023 set out on pages one to twelve and you consider that the company is exempt from an audit. |
In accordance with your instructions, we have compiled these unaudited financial statements in order to assist you to fulfil your statutory responsibilities, from the accounting records and information and explanations supplied to us. |
45 Queen Street |
Deal |
Kent |
CT14 6EY |
Date: ............................................. |